Merck KGaA to Acquire Bio-Techne for $11.3 Billion, Bolstering Life Science Tools for Cell and Gene Therapy Workflows

September 13, 2026

BioBucks United States

Overview

Merck KGaA has agreed to acquire life science tools provider Bio-Techne for $11.3 billion, a strategic move to significantly enhance its life science division. This acquisition deepens Merck KGaA’s exposure to foundational technologies critical for the rapidly expanding cell and gene therapy workflows. The substantial deal reflects an accelerating trend of consolidation and growth within the research and manufacturing tool markets supporting advanced regenerative medicines.

In Depth

Key Findings

Merck KGaA has reached an agreement to acquire Bio-Techne, a prominent life science tools provider, for $11.3 billion. This acquisition is a strategic maneuver designed to substantially expand Merck KGaA’s life science portfolio and strengthen its offerings across the entire cell and gene therapy (CGT) workflow.

Technical / Clinical Details

Bio-Techne offers a comprehensive suite of products vital for life science research and manufacturing, including cell culture media, gene editing tools, proteomics, and immunoassays. These products are indispensable at various stages of CGT development, from foundational research and process optimization to Good Manufacturing Practice (GMP) production.
Through this acquisition, Merck KGaA aims to provide more integrated and end-to-end solutions to its customers involved in the CGT value chain. This expanded offering is expected to encompass a broader range of reagents, instruments, consumables, and potentially contract development and manufacturing (CDMO) services.
In a related development, UCB acquired Neurogeneys Therapeutics, a company with NRTX-1001, a clinical-stage regenerative cell therapy for refractory mesial temporal lobe epilepsy. This private acquisition highlights the increasing interest of major pharmaceutical companies in integrating advanced cell therapy technologies for specific disease indications into their pipelines.

Background & Context

The biotech industry in 2026 is experiencing a surge in M&A activities, with the Merck KGaA-Bio-Techne deal standing out as a cornerstone transaction. Other significant acquisitions reported around the same period include Vertex’s planned acquisition of Crinetics Pharmaceuticals for approximately $10 billion and GSK’s agreement to acquire Nuvalent for $10.6 billion.

These transactions collectively underscore a strategic drive to reinforce portfolios in life science tools, precision diagnostics, and targeted therapeutic areas. The Merck KGaA acquisition is particularly indicative of the growing importance of suppliers that underpin the manufacturing and research infrastructure of the booming CGT market. Companies are consolidating to achieve vertical integration, enhance technological capabilities, and secure a competitive edge in a rapidly evolving landscape.

Strategic Significance & Outlook

The integration of Bio-Techne into Merck KGaA’s operations is expected to redefine competition within the life science tools market. The combined entity will be better positioned to offer a more expansive and seamless range of products and services essential for the development and commercialization of cell and gene therapies, thereby accelerating customer R&D efforts. This synergy is anticipated to fuel further innovation in regenerative medicine, paving the way for more groundbreaking treatments to reach patients.

Source: https://www.biobucks.co/biotech-ma-tracker-2026

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.